Novo Nordisk announced on Tuesday that it will shorten its name to Novo in everyday use as part of a strategic effort to enhance its market presence amid intensifying competition in the obesity drug sector. The Danish pharmaceutical group, known for products such as Ozempic and Wegovy, has historically been identified by its full name since its founding more than a century ago.

This rebranding initiative comes ahead of a capital markets day scheduled for next week, where Novo’s leadership, including Chief Executive Officer Mike Doustdar, is expected to outline plans to regain market share against U.S. rival Eli Lilly. Eli Lilly’s obesity treatments, Zepbound and Mounjaro, have gained traction in the United States partly due to their earlier consumer-focused launch, which has challenged Novo's position in the multibillion-dollar field.

Under Doustdar’s leadership, who took the helm last year to address the company’s recent underperformance and broaden its product base beyond diabetes and weight management drugs, Novo has made this change to create a more streamlined and recognizable brand identity. The group’s revenue remains heavily concentrated in obesity and diabetes treatments, which accounted for 93 percent of sales in the last quarter, leaving investors concerned about its limited diversification.

Market analysts have offered mixed views on the rebranding. Evan Seigerman of BMO Capital Markets noted that while the name Novo is commonly used informally among investors and analysts, the name change itself might not significantly impact the company’s performance unless accompanied by meaningful internal cultural shifts and strategic execution. He emphasized that the rebrand should not become a distraction from addressing critical business challenges.

Despite maintaining a strong performance with its obesity pill, Novo's sales forecast indicates potential flat or declining sales by as much as 6 percent for the year, adding pressure on management to demonstrate innovation and growth opportunities.

Originally founded as Nordisk in 1923 and becoming Novo Nordisk after a 1989 merger with domestic rival Novo, the company will retain Novo Nordisk as its legal name. The rebranding also includes a refreshed logo featuring its trademark Apis bull, now facing right instead of left, symbolizing the company’s forward-looking ambitions. Novo stated this updated branding will provide a consistent and recognizable way to engage with customers, partners, and other stakeholders worldwide.